Generate: Biomedicines, a Somerville, MA-based clinical stage company which specializes in generative biology, received an investment from Samsung.
The amount of the deal was not disclosed.
The company intends to use the funds to expand operations and its R&D efforts.
Founded by Flagship Pioneering in 2018, and led by CEO Mike Nally, Generate:Biomedicines is a clinical stage generative biology company. They apply AI-based optimization and de novo generation to discover and design novel protein therapeutics. The company has a pipeline of approximately 20 programs from preclinical to clinical development across oncology, immunology, and infectious diseases.
FinSMEs
18/12/2024